Immune checkpoint inhibitors (ICI) are immunotherapy drugs introduced in 2015 as first-line melanoma treatment.
A large retrospective study was conducted to examine changes in usage rate and clinical benefit of this treatment since 2015 among stage 4 melanoma patients.
Results showed that the usage rate increased gradually and reached 62.5% in 2019.
In addition, first-line ICI was linked to considerable overall survival improvements, including for patients with brain metastases.
For more info:
Use of First-Line Immune Checkpoint Inhibitors and Association With Overall Survival Among Patients With Metastatic Melanoma in the Anti-PD-1 Era
This content is provided for your general education and information only. It does not necessarily reflect Belong’s views and opinions. Belong does not endorse or support any specific product, service or treatment.
